Psychedelic suggestibility and expectancy

Psychedelic suggestibility and expectancy are not incidental complications in the book’s account of psychedelic therapy: they are among the conditions that can shape what a session becomes and what researchers conclude from it. The surrounding environment, the conduct of a therapist, what participants expect, and how an experience is later interpreted may all affect outcomes. This makes a central methodological tension unavoidable. A carefully controlled experiment can isolate a drug by stripping away human contact and context, yet those very features may help make therapy effective; meanwhile, therapeutic enthusiasm and a powerful experience can make early results look more conclusive than they are.

The Session as a Context, Not Just a Dose

At Weyburn hospital, Humphry Osmond and Abram Hoffer began to doubt that LSD’s effects on people treated for alcoholism could be understood simply as a temporary imitation of psychosis. Many patients’ accounts seemed closer to transcendence or spiritual insight. Their volunteers also showed how much the conditions of a session mattered: the environment affected the kinds of experiences people had, and an engaged, empathetic therapist seemed to help prevent a bad session. Osmond and Hoffer came to suspect that some psychotic reactions might have been produced, or intensified, by the clinical atmosphere itself—a metaphorical white room and a white-coated clinician—rather than by the drug alone.

The contrast became concrete when the Addiction Research Foundation in Toronto tried to replicate the Saskatchewan trials in the early 1960s. Seeking stronger controls, clinicians placed participants in neutral rooms and instructed staff not to engage with them during their trips, apart from administering an extensive questionnaire. Volunteers were restrained, blindfolded, or both. The results did not match the Saskatchewan outcomes; more than a few participants had terrifying experiences. The poorer results could support two readings at once: the treatment appeared less successful under rigorously controlled conditions, and the absence of supportive attention and a favorable setting may itself have undermined it. In this history, context is not merely noise around the treatment. It is part of the treatment’s operating conditions, while also making it harder to say precisely what the drug contributes.

Expectations and the Strength of a Claim

The Concord Prison Experiment illustrates how suggestibility and expectation can complicate the interpretation of apparent success. In 1961, Timothy Leary and Ralph Metzner proposed testing whether psilocybin could reduce repeat imprisonment. Thirty-two inmates in a maximum-security prison received psilocybin in sessions held at the prison; one member of Leary’s team took the drug alongside them, while another remained sober to observe and take notes. A second group received neither drugs nor special treatment. Leary reported that ten months after release, 25 percent of the psilocybin group had returned to jail, compared with 80 percent of the control group.

That dramatic contrast did not survive later scrutiny. Rick Doblin reconstructed the outcomes inmate by inmate and concluded that the difference in recidivism was not statistically significant; methodological weaknesses had also drawn criticism at the time. The episode shows why expectation matters beyond the subjective session. Researchers who believe a therapy will work may interpret limited or ambiguous outcomes in its favor, and compelling headline numbers can outlast the qualifications that produced them. A positive result may be a meaningful signal, but it is not automatically proof that the drug caused the difference.

The same caution applies to more recent clinical evidence, though it does not erase its promise. In the combined New York University and Johns Hopkins cancer trials, about 80 percent of patients showed clinically significant reductions in anxiety and depression, lasting at least six months. The intensity of participants’ mystical experiences closely correlated with the extent of symptom relief. Yet the trials together included only eighty people, and the association between mystical intensity and improvement does not by itself establish what caused the change. Correlation makes the relationship worth investigating; it does not settle whether the drug, the experience, the therapeutic setting, participants’ expectations, or some combination explains the outcome.

Open Studies, Enthusiasm, and the Placebo Problem

Robin Carhart-Harris’s early study of psilocybin for treatment-resistant depression makes the limits of expectancy especially visible. The first group consisted of twelve people—six men and six women—who had already tried at least two treatments without success. There was no control group, and participants knew they were receiving psilocybin. After a week, all showed improvement, and two-thirds were depression-free. Seven still showed substantial benefit at three months. When the study expanded to twenty volunteers, six remained in remission after six months, while others had relapsed to varying degrees. The treatment was well tolerated, with no adverse events reported, and the benefits for many participants were rapid and marked. But without a control group, the study could not isolate the drug’s effects from expectation, therapeutic attention, or other influences.

The book places such findings beside a broader warning about early medical enthusiasm. Small studies can select volunteers most likely to respond; participants receive the concentrated attention of highly trained and dedicated therapists; and researchers may be invested in finding a positive effect. The placebo effect may also be unusually strong when a treatment is new. These considerations do not show that psychedelic therapy is ineffective. They explain why promising early outcomes should be treated as signals requiring confirmation rather than as definitive evidence of cure. A striking result can justify a larger trial without answering every question that generated it.

Meaning as an Effect of the Drug

Suggestibility is not presented only as a rival explanation for psychedelic effects. Research on LSD and serotonin 2A receptors offers a possible biological account of how experiences acquire personal significance. In work conducted in Franz Vollenweider’s lab, blocking those receptors with ketanserin also blocked LSD-induced attribution of personal relevance to stimuli that had previously seemed meaningless. The finding suggests that 5-HT2A receptor activation plays a role in generating or assigning meaning during an LSD state.

That result adds a mechanism to the debate, but it does not collapse the distinction between pharmacology and expectation. A receptor-level finding can help explain how LSD changes the processing of significance; it cannot, on its own, determine how a participant will interpret a particular experience or how lasting therapeutic benefits arise. The book’s account therefore holds two ideas together: the drug can alter the conditions under which meaning is perceived, and the session’s human and psychological context can shape what that altered meaning becomes.

A Methodological and Therapeutic Tension

Across the historical trials and newer clinical studies, expectancy is both a possible source of bias and a feature of the therapeutic encounter. Removing interaction may improve experimental control while producing a harsher session; supportive attention may improve the experience while making it harder to separate drug effects from care. The tension cannot be resolved by treating either the molecule or the setting as the sole explanation. Instead, the evidence calls for studies that take the conditions of treatment seriously while testing benefits in larger and more controlled populations.

The concept thus sets a limit on easy conclusions in both directions. The dramatic outcomes do not establish that psychedelics are a cure-all, particularly when early samples are small and expectation is difficult to separate from treatment. Nor does the influence of expectation make the experience or its effects unreal. It identifies a central question for research: how the drug, the person’s expectations, the therapist, and the setting work together—and which parts of that interaction reliably contribute to improvement.